title: Chemotherapy of advanced squamous carcinoma of the cervix: a phase I-II study of high-dose cisplatin and cyclophosphamide. A pilot study of the Gynecologic Oncology Group.
abstract: Sixteen patients with recurrent squamous cell carcinoma of the cervix were treated with a combination of cyclophosphamide and cisplatin to determine a tolerable dose schedule, major adverse effects, and a general estimate of response rate and duration. Toxicity was substantial with a dose of cyclophosphamide 1000 mg/m2 and cisplatin 100 mg/m2 given intravenously every 3 weeks. Renal, hematologic, and gastrointestinal toxicities were severe. Of the 12 patients with measurable disease, there were two complete responses and three partial responses for a response rate of 42%. The median duration of response was 24 weeks. Six patients remained stable during therapy and one patient had progression of disease. Use of cyclophosphamide and cisplatin in combination chemotherapy for recurrent carcinoma of the cervix was tolerable but associated with substantial toxicity. The responses seen in this study are encouraging and warrant further comparative trials with this combination of drugs.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D003520:Cyclophosphamide; D002945:Cisplatin